Advertisement

Strahlentherapie und Onkologie

, Volume 175, Supplement 2, pp 82–84 | Cite as

Conformal proton beam therapy of prostate cancer — update on the loma linda university medical center experience

  • Carl J. Rossi
Clinical Aspects of Hadron Therapy

Abstract

Background

The ability to eradicate localized prostate cancer is dependent upon the radiation dose which can be delivered to the prostate. This dose is often limited by the tolerance of normal organs (rectum, bladder). Conformal beam therapy takes advantage of the unique depth dose characteristics of heavy charged particles (the Bragg Peak) to escalate the radiation dose delivered to the prostate while minimizing treatment-related toxicity.

Method

643 patients with localized prostate cancer were treated with protons alone or a combination of protons and photons. All treatment was planned on a 3-D planning system and all received doses between 74–75 CGE (Cobalt Gray Equivalent) at 1.8–2.0 CGE/day. Patients were evaluated for toxicity and response to treatment.

Results

Five-year actuarial clinical and biochemical disease-free survival rates for the entire group are 89 and 79% respectively. A statistically significant difference in biochemical disease-free survival was seen between patients in the “early” (T1b-2b, PSA<15) and “advanced” (T1b-2b, PSA>15 or T2c-T4, PSA<50) subgroups (89% vs. 68% at 4.5 years, p<0.001). A PSA nadir of less than 0.51 ng/ml predicted for the highest chance of freedom from biochemical recurrence. Minimal radiation proctitis was seen in 21% of patients; toxicity of greater serverity was seen in less than 1%.

Conclusion s

Conformal proton beamt therapy produced high rates of response and minimal toxicity. A phase III dose escalation trial is in progress to help define the optimum radiation dose for the treatment of early stage prostate cancer.

Key Words

Radiotherapy Proton Prostate PSA Prognostic factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hanks G, Martz K, Diamond J. The effect of dose on local control of prostate cancer. Int J radiat Oncol Biol Phys 1988;15:1299–305.PubMedGoogle Scholar
  2. 2.
    Hanks G, Hanlon A, Schultheiss T, et al. Early prostate cancer: the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol 1994;152:1775–80.PubMedGoogle Scholar
  3. 3.
    Hanks G, Lee W, Schultheiss T. Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J Urol 1995;154:456–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Archambeau J, Bennett G, Levine G, et al. Proton radiation therapy. Radiology 1974;110:445–57.PubMedGoogle Scholar
  5. 5.
    Wilson R. Radiological use of fast protons. Radiology 1946;47:487–91.Google Scholar
  6. 6.
    Slater J, Archambeau J, Miller D, et al. The proton treatment center at Loma Linda University Medical Center: rationale for and description of its development. Int J Radiat Oncol Biol Phys 1992;22:383–9.PubMedGoogle Scholar
  7. 7.
    Slater J, Yonemoto L, Rossi C, et al. Conformal proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 42;2:299–304.Google Scholar
  8. 8.
    Partin A, Pound C, Clemens J, et al. Serum PSA after anatomic radical prostatectomy: The Jon Hopkins experience after ren years. Urol Clin N Am 1993;20:713–25.Google Scholar
  9. 9.
    Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al. Results of 3-D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:311–7.PubMedGoogle Scholar
  10. 10.
    Blasko JC, Wallner K, Grimm PD, et al. Prostate specific antigen based disease control following ultrasound guided iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;54(3):1096–9.Google Scholar
  11. 11.
    Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14(2):449–53.PubMedGoogle Scholar

Copyright information

© Urban & Vogel 1999

Authors and Affiliations

  • Carl J. Rossi
    • 1
  1. 1.Dept. of Radiation MedicineLoma Linda University Medical CenterLoma LindaU.S.A.

Personalised recommendations